Q4 2025 Torrent Pharmaceuticals Ltd Earnings Call Transcript
Key Points
- Torrent Pharmaceuticals Ltd (BOM:500420) reported an 8% year-on-year increase in revenues for Q4 FY25, reaching INR2,959 crore.
- The company's operating EBITDA grew by 9% YoY, with a margin of 32.6%, indicating strong operational efficiency.
- The India business saw a robust growth of 12%, outperforming the Indian Pharmaceutical Market (IPM) growth of 8%.
- The US business experienced a 15% growth, driven by enhanced volume of purchases under existing contracts.
- Torrent Pharmaceuticals Ltd (BOM:500420) continues to expand its market presence, with 21 brands in the top 500 of the IPM and 14 brands achieving over INR100 crore in sales.
- The Brazilian real depreciated by 11% during the quarter, impacting the company's financial performance in Brazil.
- There was a channel destocking in Brazil due to expectations of low price increases, affecting sales for Q4.
- The German business only grew by 2%, indicating slower growth compared to other regions.
- The insulin business is expected to maintain a flat quarterly run rate of INR75 crore, with no significant growth anticipated.
- The US market faces challenges with generic pricing not being very attractive, impacting profitability.
Ladies and gentlemen, good day, and welcome to Q4 FY25 earnings conference call of Torrent Pharma. (Operator Instructions) Please note that this conference is being recorded. I now hand the conference over to Mr. Sudhir Menon, Executive Director, Finance and CFO. Thank you, and over to you, sir.
Thank you. Good evening, and welcome to the fourth quarter earnings call for FY25. We continue to see strong performance in our branded markets, which accounted for 73% of the overall revenue this quarter. India business growth for quarter four is 12%. Brazil, our constant currency growth for the quarter is 5%.
There was a channel destocking in quarter four due to an expectation of low price increase for '25, '26, which has impacted sales for quarter four. The Brazilian real depreciation for the quarter was 11%. On the generic side, the US business grew at 15% and Germany grew at 2%. We continue to win incremental tenders in Germany, which should help us deliver
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
